Faeth Therapeutics (FTH) vs Zevra Therapeutics (ZVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Faeth Therapeutics (FTH) has outperformed Zevra Therapeutics (ZVRA) over the past year, gaining 123.1% versus a gain of 3.4%. Over five years, ZVRA leads with a +12.6% price change compared with -83.2% for FTH. Zevra Therapeutics is the larger company by market cap ($653.2 million vs $651.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FTH | ZVRA |
|---|---|---|
| Share price | $25.21 | $11.00 |
| Market cap | $651.44M | $653.22M |
| 1-day change | -1.56% | -0.72% |
| YTD return | +140.02% | +22.77% |
| 1-year return | +123.08% | +3.38% |
| 5-year return | -83.22% | +12.59% |
| P/E ratio (TTM) | — | 11.96 |
| Forward P/E | — | 10.22 |
| EPS (TTM) | $-60.86 | $0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $42.14 | $15.04 |
| 52-week low | $7.45 | $8.01 |
| Distance from 52-week high | -40.18% | -26.84% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +124.79% | +127.27% |
| Average volume | 354.81K | 1.11M |
| Shares outstanding | 25.84M | 59.38M |
| Employees | 29 | 61 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FTH has outperformed ZVRA by 119.7 percentage points over the past year.
About Faeth Therapeutics
FTH stock →Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Zevra Therapeutics
ZVRA stock →Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 61 employees
FTH vs ZVRA FAQ
Which is bigger, Faeth Therapeutics or Zevra Therapeutics?
Zevra Therapeutics (ZVRA) is larger, with a market capitalization of $653.22M compared with $651.44M for Faeth Therapeutics (FTH).
Which stock has performed better over the past year, FTH or ZVRA?
FTH returned +123.08% over the past 12 months, compared with +3.38% for ZVRA (price return, excluding dividends). Past performance does not predict future results.
Are Faeth Therapeutics and Zevra Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.